Phase 2 N=32 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Leukemia
Primary: Median Progression-free Survival (PFS) for Patients Less Than 60 Years of Age — 52.1 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 1 N=164 Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
Staphylococcal Infections · Yeast Infections · Candidiasis
Primary: Number of Participants With Treatment Emergent Adverse Events — 35; 33; 30; 36 participants
Phase 4 N=37 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Human Immunodeficiency Virus Infection
Primary: Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV — 80; 478; 213 cells / mm^2…
N/A N=72 Nonpharmacologic Reduction of Periprocedural Distress and Drug Use
Dental Anxiety · Dental Pain · Drug Use
Primary: Number of Participants With Complete On-Site Data Sets — 37; 35 Participants
Phase 2 N=26 A Study of CLR325 in Chronic Stable Heart Failure Patients.
Chronic Stable Heart Failure
Primary: Number of Patients With Adverse Events, Serious Adverse Events and Death — 1; 2; 4; 7 Participants
Phase 1 N=5 MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
HIV-1 Infection
Primary: Number of Participants With at Least One Adverse Event (AE) — 4 Participants
Phase 2 N=79 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/m^2
N/A N=44 High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression
Spinal Cord Compression Due to Metastasis to Spine
Primary: Number of Participants Who Were Alive at 6 Months After Radiotherapy Without Deterioration of Motor Function During (or Directly After) Radiotherapy and Freedom From…
Phase 1 N=64 Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
Acute Myelogenous Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 32; 29; 3; 21 Participants
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=9 Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Metastatic Breast Cancer · Brain Metastases
Primary: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) — 88.9 percentage of participants
N/A N=39 Magna Mitral - 23mm
Mitral Heart Valve Disease
Primary: Percent of Early Adverse Events Divided — 8.3; 0.0; 0.0; 0.0 percentage of subjects
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
N/A N=50 The Effect of Goal-directed Therapy Guided by Stroke Volume Variation and Cardiac Index in Non-severe Surgical Patients
Fluid Therapy
Primary: Number of Days Needed for Anal Exsufflation After Surgery — 3.8; 2.7 days